Atara Biotherapeutics Inc ATRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
-
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
-
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
-
Atara Biotherapeutics Stock Falls After Surprise FDA Refusal to Approve Ebvallo
Trading Information
- Previous Close Price
- $9.18
- Day Range
- $8.96–9.35
- 52-Week Range
- $3.92–19.15
- Bid/Ask
- $8.87 / $9.34
- Shares Outstanding
- 10.04M
- Market Cap
- $89.94M
- Volume/Avg
- 12,450 / 47,462
Key Statistics
- Price/Earnings (Normalized)
- 2.25
- Price/Sales
- 21.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.atarabio.com
Valuation
|
Metric
|
ATRA
|
|---|---|
Price/Earnings (Normalized) | 2.25 |
Price/Book Value | — |
Price/Sales | 21.06 |
Price/Cash Flow | — |
Price/Earnings
ATRA
Financial Strength
|
Metric
|
ATRA
|
|---|---|
Quick Ratio | 1.49 |
Current Ratio | 1.98 |
Interest Coverage | −5.05 |
Quick Ratio
ATRA
Profitability
|
Metric
|
ATRA
|
|---|---|
Return on Assets (Normalized) | −53.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@?kf<Vk | LOCK|BQTbK | $127B | |||
| Moderna Inc
MRNA
| LOCK|#?TNW#? | LOCK|Dxc | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>Zp#<!N | LOCK|$GBw | $81B | |||
| argenx SE ADR
ARGX
| LOCK|vs?ZhF | LOCK|$C | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&@t?wxW | LOCK|^$ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|t%^$#?^ | LOCK|tFY%x | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KlCv$h? | LOCK|G$yX | $27B | |||
| Incyte Corp
INCY
| LOCK|^s@GKx% | LOCK|mLC | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<ZG%q^> | LOCK|Y#@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|QKKf#y# | LOCK|pYf | $14B |
United States